New Indication: Oral contraceptive approved for acne
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Survey: Part B Price Negotiation Could have Significant Impact on Providers
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
Listen
Intercept Withdraws Ocaliva from Market After FDA Raises Safety Concerns
New Data at EADV Could Offer Hope, Address Gaps in Dermatology Care
Big Beautiful Bill Reduces Drugs Eligible for Price Negotiations
ICER Finds GLP-1 Drugs Cost-Effective but Warns of Major Budget Strain